Advances in the clinical management of GVHD.

The principal cause of mortality and morbidity following hematopoietic cell transplantation (HCT) is graft-versus-host disease (GVHD). Studies in murine models have revealed that inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha) promote destruction of host tissue following HCT. Elevated plasma levels of soluble TNF receptor 1 have been associated with patients with GVHD and blocking TNF-alpha in experimental models has shown a reduced incidence of GVHD. Based on this finding, patients with new onset GVHD were treated with steroids plus the TNF-alpha inhibitor, etanercept, on a previously reported pilot trial (n=20) and a phase 2 trial (n=41) and their outcomes were compared with those of contemporaneous patients with GVHD (n=99) whose initial therapy was steroids alone. Patients treated with etanercept were more likely to achieve CR than were patients treated with steroids alone. Plasma TNFR1 levels, a biomarker for GVHD activity, were elevated at GVHD onset and decreased significantly only in patients with CR. A four protein fingerprint of IL-2Ralpha, TNFR1, IL-8, and HGF in the plasma has been identified to predict whether a patient will be at high-risk for GVHD based on biomarker analysis. In univariate and multivariate analysis, this four-protein fingerprint has shown a strong association with the grade of acute GVHD, and it can stratify patients into low- and high-risk groups and can be used as a laboratory-based screening method, to diagnose and perhaps treat patients preemptively.

[1]  A. Bacigalupo,et al.  Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. , 2006, Blood.

[2]  Thomas M Braun,et al.  A biomarker panel for acute graft-versus-host disease. , 2009, Blood.

[3]  Thomas Braun,et al.  Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. , 2008, Blood.

[4]  T. Braun,et al.  Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. , 2007, Blood.

[5]  J. Bathon,et al.  Serious Infections Associated with Anticytokine Therapies in the Rheumatic Diseases , 2004, Journal of intensive care medicine.

[6]  R. Soiffer,et al.  Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. , 2003, Blood.

[7]  P. Reddy.  Pathophysiology of acute graft‐versus‐host disease , 2003, Hematological oncology.

[8]  J. Crawford,et al.  Differential roles of IL-1 and TNF-α on graft-versus-host disease and graft versus leukemia , 1999 .

[9]  K. Welte,et al.  Cytokines in Hemopoiesis, Oncology, and AIDS II , 1992, Springer Berlin Heidelberg.

[10]  B. Andersson,et al.  Tumor necrosis factor- (cid:1) blockade for the treatment of acute GVHD , 2004 .

[11]  W. Wilmanns,et al.  Sequential Release of Tumor Necrosis Factor Alpha and Tumor Necrosis Factor Receptors in Complications of Human Bone Marrow Transplantation , 1992 .

[12]  J. Wagner,et al.  Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  J. Ferrara,et al.  Immunobiology of acute graft-versus-host disease. , 2003, Blood reviews.

[14]  W. Leisenring,et al.  An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. , 2006, Blood.